Evidence map›Paper›PMID 34582834›Full record

ReviewPharmacology & therapeutics2022

Compartmentalization of Sphingolipid metabolism: Implications for signaling and therapy.

Daniel Canals, Christopher J Clarke

Abstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Metabolic Signature ofJournal of personalized medicine · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel CanalsDepartment of Medicine and the Cancer Center, Stony Brook University, Stony Brook, NY, USA. Electronic address: daniel.canals@stonybrookmedicine.edu.
Christopher J ClarkeDepartment of Medicine and the Cancer Center, Stony Brook University, Stony Brook, NY, USA. Electronic address: christopher.clarke@stonybrookmedicine.edu.

Funding

Dihydroceramide desaturase (DES1) as a mediator of receptor tyrosine kinase-driven metastasis in breast cancerR01CA248014 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI CLARKE, CHRISTOPHER JAMES · 2021 to 2025
$1.8M
Neutral sphingomyelinase-2 as a mediator of Doxorubicin-induced cardiotoxicityR01CA248080 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI CLARKE, CHRISTOPHER JAMES · 2021 to 2025
$1.8M
NCI NIH HHS R01 CA248014NCI NIH HHS R01 CA248080
6 · The paper itself

Abstract

Sphingolipids (SLs) are a family of bioactive lipids implicated in a variety of cellular processes, and whose levels are controlled by an interlinked network of enzymes. While the spatial distribution of SL metabolism throughout the cell has been understood for some time, the implications of this for SL signaling and biological outcomes have only recently begun to be fully explored. In this review, we outline the compartmentalization of SL metabolism and describe advances in tools for investigating and probing compartment-specific SL functions. We also briefly discuss the implications of SL compartmentalization for cell signaling and therapeutic approaches to targeting the SL network.

Indexed as

Lipid MetabolismSphingolipidsHumansSignal TransductionSphingolipids

Identifiers

PMID34582834
PMCPMC9619385

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.